Concord Biotech Q1 Results: Earnings Call Scheduled for Aug 3 to Discuss Q1FY27 Performance

1 min read     Updated on 28 Jul 2026, 09:28 PM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Concord Biotech Limited announces its Q1FY27 earnings call for August 3, 2026. Key executives including Sudhir Vaid and Raviraj Karia will discuss standalone and consolidated financial results. The call complies with SEBI Regulation 30 disclosures.

powered bylight_fuzz_icon
46799902

*this image is generated using AI for illustrative purposes only.

Concord Biotech Limited will host an earnings conference call on Monday, August 03, 2026, at 3:30 PM IST to discuss its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The event provides investors with direct access to management for insights into the company's operational performance and strategic outlook following the declaration of its Q1FY27 results.

The disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para A of Schedule III. Paritosh Trivedi, Company Secretary and Compliance Officer, signed the submission to the National Stock Exchange of India Limited and BSE Limited on July 28, 2026. The filing confirms that the earnings call invite has been enclosed with the exchange submissions for record-keeping purposes.

Management Participants

Senior leadership from Concord Biotech will participate in the discussion to address investor queries regarding the quarterly performance. The confirmed participants include:

Executive Designation
Sudhir Vaid Chairman & Managing Director
Ankur Vaid Joint Managing Director and CEO
Raviraj Karia Chief Financial Officer
Prakash Sajnani AVP, Accounts & Finance

Conference Call Details

The conference call is organized in association with IIFL. Participants can join via pre-registration through the provided Diamond Pass link or by dialing the designated numbers. The schedule accommodates global investors with simultaneous time zone conversions listed for Hong Kong, Singapore, the UK, and the USA.

Region Dial-in Number
India (Primary) +91 22 6280 1259 / +91 22 7115 8160
USA 1-866 746 2133
UK 0-808 101 1573
Singapore 800-101 2045
Hong Kong 800-964 448

For further information or registration assistance, investors may contact Naman Bagrecha, Rahul Jeewani, Aman Goyal, or Vighnesh Indure at IIFL Capital Markets using the provided contact details.

Historical Stock Returns for Concord Biotech

1 Day5 Days1 Month6 Months1 Year5 Years
-0.02%-5.91%-0.46%+2.79%-32.67%+33.23%

How might Concord Biotech's Q1FY27 revenue and margin performance influence its valuation relative to generic pharmaceutical peers in the current market cycle?

What specific strategic initiatives or pipeline developments is management likely to highlight to justify future growth projections during the conference call?

Will the company address any potential regulatory headwinds or supply chain disruptions that could impact its operational outlook for the remainder of FY27?

Concord Biotech fixes record date for ₹7.55 dividend

1 min read     Updated on 09 Jul 2026, 04:34 AM
scanx
Reviewed by
Shraddha JScanX News Team
AI Summary

Concord Biotech Limited has fixed July 24, 2026, as the record date for a final dividend of ₹7.55 per share, subject to shareholder approval at the 41st AGM scheduled for July 31, 2026. The meeting agenda includes the adoption of audited financial statements for FY26, the re-appointment of a director, and the ratification of cost auditor remuneration.

powered bylight_fuzz_icon
44876332

*this image is generated using AI for illustrative purposes only.

Concord Biotech Limited has fixed Friday, July 24, 2026, as the record date to determine shareholder eligibility for a final dividend of ₹7.55 per equity share for the financial year ended March 31, 2026. The dividend, equivalent to 755% on the face value of ₹1 each, is subject to approval by shareholders at the 41st Annual General Meeting. If approved, the payment will be made by August 30, 2026, subject to deduction of tax at source.

The company will hold its AGM on Friday, July 31, 2026, at 12:00 Noon through Video Conferencing and Other Audio-Visual Means. Pursuant to Regulation 42 of the SEBI Listing Regulations, the Register of Members and Share Transfer Books will be closed from Saturday, July 25, 2026, to Friday, July 31, 2026 (both days inclusive). The meeting agenda includes the adoption of audited financial statements for FY26 and the re-appointment of Mr. Ankur Vaid as Director.

Shareholders will also vote on the appointment of Mrs. Ekta Gupta as an Independent Director for a term of five years effective from June 01, 2026. Additionally, the company seeks approval to enhance the limit for loans, guarantees, and securities to subsidiaries, associates, and joint ventures to ₹500 Crores from the existing limit of ₹115 Crores. The ratification of remuneration for Cost Auditors, M/s. Dalwadi & Associates, at ₹3,70,000 plus applicable Goods and Services Tax for FY27 is also on the agenda.

Key Meeting Details

Event Date Time
Record Date July 24, 2026
Book Closure Start July 25, 2026
Book Closure End July 31, 2026
Remote E-Voting Start July 28, 2026 9:00 A.M. (IST)
Remote E-Voting End July 30, 2026 5:00 P.M. (IST)
41st AGM July 31, 2026 12:00 Noon (IST)

The Notice of AGM along with the Annual Report 2025-26 will be sent electronically to members, with physical copies available upon request. These documents will also be accessible on the company's website and the websites of BSE Limited and National Stock Exchange of India Limited.

Historical Stock Returns for Concord Biotech

1 Day5 Days1 Month6 Months1 Year5 Years
-0.02%-5.91%-0.46%+2.79%-32.67%+33.23%

What strategic rationale is driving the proposed 335% increase in the limit for loans, guarantees, and securities to subsidiaries?

How will the substantial capital outflow from the 755% dividend impact Concord Biotech's planned capital expenditure or R&D investments for FY27?

What specific growth initiatives or acquisitions are anticipated that necessitate the enhanced financial flexibility provided by the increased loan limits?

More News on Concord Biotech

1 Year Returns:-32.67%